Masimo Corp Files Q3 2024 10-Q
Ticker: MASI · Form: 10-Q · Filed: Nov 6, 2024 · CIK: 937556
| Field | Detail |
|---|---|
| Company | Masimo CORP (MASI) |
| Form Type | 10-Q |
| Filed Date | Nov 6, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Masimo Corp's Q3 2024 10-Q is in. Get the latest financials.
AI Summary
Masimo Corporation filed its 10-Q for the period ending September 28, 2024. The filing details the company's financial performance and operational status. Key financial data and business segments are presented, reflecting the company's activities during the third quarter of 2024.
Why It Matters
This filing provides investors and analysts with the latest financial and operational details for Masimo Corp, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — 10-Q filings are standard disclosures, but the specific financial performance and any new risks mentioned within can significantly impact a company's stock.
Key Numbers
- 2024 Q3 — Reporting Period (Indicates the specific quarter for which financial data is reported.)
Key Players & Entities
- MASIMO CORP (company) — Filer
- 20240928 (date) — Period of Report
- 20241106 (date) — Filed as of Date
- 949-297-7000 (phone_number) — Business Phone
FAQ
What is the fiscal year end for Masimo Corp?
Masimo Corp's fiscal year ends on December 28.
What is the SEC file number for Masimo Corp?
The SEC file number for Masimo Corp is 001-33642.
In which state was Masimo Corp incorporated?
Masimo Corp was incorporated in Delaware (DE).
What is the business address of Masimo Corp?
The business address is 52 Discovery, Irvine, CA 92618.
What is the SIC code for Masimo Corp?
The Standard Industrial Classification (SIC) code is 3845, for Electromedical & Electrotherapeutic Apparatus.
Filing Stats: 4,744 words · 19 min read · ~16 pages · Grade level 7.9 · Accepted 2024-11-05 21:27:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MASI The Nasdaq Stock Marke
Filing Documents
- masi-20240928.htm (10-Q) — 2619KB
- masi-20240928x10qex35.htm (EX-3.5) — 3KB
- masi-20240928x10qex101.htm (EX-10.1) — 72KB
- masi-20240928x10qex102.htm (EX-10.2) — 48KB
- masi-20240928x10qex103.htm (EX-10.3) — 351KB
- masi-20240928x10qex104.htm (EX-10.4) — 17KB
- masi-20240928x10qex105.htm (EX-10.5) — 28KB
- masi-20240928x10qex106.htm (EX-10.6) — 31KB
- masi-20240928x10qex211.htm (EX-21.1) — 53KB
- masi-20240928x10qex311.htm (EX-31.1) — 9KB
- masi-20240928x10qex312.htm (EX-31.2) — 9KB
- masi-20240928x10qex321.htm (EX-32.1) — 9KB
- image_45.jpg (GRAPHIC) — 21KB
- masi-20240928_g1.jpg (GRAPHIC) — 199KB
- 0000937556-24-000109.txt ( ) — 14045KB
- masi-20240928.xsd (EX-101.SCH) — 82KB
- masi-20240928_cal.xml (EX-101.CAL) — 132KB
- masi-20240928_def.xml (EX-101.DEF) — 418KB
- masi-20240928_lab.xml (EX-101.LAB) — 992KB
- masi-20240928_pre.xml (EX-101.PRE) — 729KB
- masi-20240928_htm.xml (XML) — 1985KB
Financial Information
PART I. Financial Information
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited): Condensed Consolidated Balance Sheets as of September 28, 2024 and December 30, 2023 3 Condensed Consolidated Statements of Operations for the three and nine months ended September 28, 2024 and September 30, 2023 4 Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 28, 2024 and September 30, 2023 5 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 28, 2024 and September 30, 2023 6 Condensed Consolidated Statements of Cash Flows for the nine months ended September 28, 2024 and September 30, 2023 8 Notes to Condensed Consolidated Financial Statements 9
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 51
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 63
Controls and Procedures
Item 4. Controls and Procedures 64
Other Information
PART II. Other Information
Legal Proceedings
Item 1. Legal Proceedings 64
Risk Factors
Item 1A. Risk Factors 65
Other Information
Item 5. Other Information 98
Exhibits
Item 6. Exhibits 99
Signatures
Signatures 101 2 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in millions, except par values) September 28, 2024 December 30, 2023 ASSETS Current assets Cash and cash equivalents $ 158.5 $ 163.0 Trade accounts receivable, net of allowance for credit losses of $ 6.0 million and $ 4.8 million at September 28, 2024 and December 30, 2023, respectively (1) 371.0 355.5 Inventories 569.9 545.0 Other current assets 180.5 168.4 Total current assets 1,279.9 1,231.9 Lease receivable, non-current 64.2 71.4 Deferred costs and other contract assets 59.6 57.3 Property and equipment, net 417.9 424.4 Customer relationships, net - (Note 9) 169.0 177.7 Acquired technologies, net - (Note 9) 115.3 129.4 Other intangible assets, net - (Note 9) 120.9 112.8 Trademarks - (Note 9) 235.6 232.4 Goodwill 412.5 407.7 Deferred tax assets 107.1 107.2 Other non-current assets 105.8 89.3 Total assets $ 3,087.8 $ 3,041.5 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities Accounts payable $ 280.8 $ 251.5 Accrued compensation 76.0 62.6 Deferred revenue and other contract liabilities, current 84.5 87.3 Other current liabilities 196.3 162.4 Total current liabilities 637.6 563.8 Long-term debt 733.2 871.7 Deferred tax liabilities 111.3 111.7 Other non-current liabilities 142.5 129.5 Total liabilities 1,624.6 1,676.7 Commitments and contingencies - (Note 24) Stockholders' equity Preferred stock, $ 0.001 par value; 5.0 million shares authorized; 0 shares issued and outstanding — — Common stock, $ 0.001 par value; 100.0 million shares authorized; 53.5 million and 52.8 million shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively 0.1 0.1 Treasury stock, 19.5 million and 19.5 million shares at September 28, 2024 and December 30, 2023, respectively ( 1,169.2 ) ( 1,169.2 ) Additional paid-in capital 828.4 783.4 Accumulated other comprehensive loss ( 36.6 ) ( 45.3 ) Retained earnings 1